Tagged with Opinion,

“Watch Out! Unsophisticated AI in Healthcare Can Perpetuate Bias”
Megatrends from the 2019 Deloitte Life Sciences Outlook
Investing in Canadian Health: We Know the Cost, but Can We Talk About Value?
Year in Review – Transformational Transactions Dominated 2018
“Restricting Drug Patent Settlements is Bad for US Patients”
Perspectives from J.P. Morgan’s 2019 Health Care Investor Conference
The Ideal Pharma Country Manager: South Korea (Egon Zehnder)
Real-World Evidence – A Game Changer for Pharma
Digital Therapeutics Need the Scrutiny of All Health Stakeholders
Mythbusting: Patient Access to Rare Disease Treatments
Healthcare Politics in 2019
The Long and Short of Drug Shortages in America
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here